VC  The Column Group

     Office Locations:

1700 Owens Street, Suite 500
San Francisco, CA 94158
Phone: 415-865-2050
Fax: 415-255-2048



  • Early
  • Expansion
  • Growth
  • Seed



  • Life Sciences & Healthcare



    The Column Group is a venture capital firm dedicated to creating the next generation of biotechnology companies. The firm will invest in approximately 10-12 disease-focused drug discovery companies (per fund), each with the potential to become a leader in their respective field(s). Typically, Column will commit $15M to $30M per company, fostering their growth from seed and early stage to later stages of development. The Column Group will primarily focus on early stage drug discovery companies, an area currently underserved by many biotech venture capital funds. The firm is currently evaluating opportunities in the areas of cancer, inflammation, infectious disease, metabolic disorders, cardiovascular disease and nervous system disorders.



      Fund Name



    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or Silicon Valley Database subscription.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    David V. Goeddel Ph.D. Managing Partner
    James Evangelista Director of Finance
    Peter Svennilson Managing Partner
    Sue Murakami Manager of Administration
    Tim Kutzkey Ph.D. Managing Partner


    Recent Funding Events (trailing 12 months):







      FLX Bio



      Series C


      Exonics Therapeutics



      Series A


      Gritstone Oncology



      Series B


      Effector Therapeutics



      Series C


    Portfolio companies include:

      3-V bioscienes
        web link

      Aragon Pharmaceuticals
        web link

      Arcus Biosciences
        web link

      Constellation Pharmaceuticals
        web link

      Cyterix Pharmaceuticals
        web link

      Effector Therapeutics
        web link

      Exonics Therapeutics
        web link

      FLX Bio
        web link

      Gritstone Oncology
        web link

        web link

      Immune Design
        web link

      NGM Biopharmaceuticals
        web link

        web link

      ORIC Pharmaceuticals
        web link

      Peloton Therapeutics
        web link

      PTC Therapeutics
        web link

      REVOLUTION Medicines
        web link


    Recent News: